Modality
ASO
MOA
PCSK9i
Target
TIM-3
Pathway
JAK/STAT
RSV
Development Pipeline
Preclinical
Sep 2017
→ Oct 2028
PreclinicalCurrent
NCT04874604
2,666 pts·RSV
2022-09→TBD·Not yet recruiting
NCT04117857
1,297 pts·RSV
2017-09→2028-10·Terminated
3,963 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-212.6y awayInterim· RSV
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Termina…
Preclinical
Not yet…
Catalysts
Interim
2028-10-21 · 2.6y away
RSV
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04874604 | Preclinical | RSV | Not yet recr... | 2666 | UPDRS |
| NCT04117857 | Preclinical | RSV | Terminated | 1297 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 |